Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Harvard Business School
Teva
Daiichi Sankyo
Dow
Healthtrust
Cerilliant
Cipla
US Department of Justice

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202107

« Back to Dashboard

NDA 202107 describes KORLYM, which is a drug marketed by Corcept Therap and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the KORLYM profile page.

The generic ingredient in KORLYM is mifepristone. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the mifepristone profile page.
Summary for 202107
Tradename:KORLYM
Applicant:Corcept Therap
Ingredient:mifepristone
Patents:3
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 202107
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KORLYM mifepristone TABLET;ORAL 202107 NDA Corcept Therapeutics Inc 76346-073 N 76346-073-01
KORLYM mifepristone TABLET;ORAL 202107 NDA Corcept Therapeutics Inc 76346-073 N 76346-073-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength300MG
Approval Date:Feb 17, 2012TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 17, 2019
Regulatory Exclusivity Use:FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
Patent:➤ Sign UpPatent Expiration:Aug 27, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:TREATING CUSHING'S SYNDROME
Patent:➤ Sign UpPatent Expiration:Aug 15, 2036Product Flag?Substance Flag?Delist Request?
Patented Use:TREATING CUSHING'S SYNDROME

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
US Army
Julphar
Mallinckrodt
Argus Health
Teva
Deloitte
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.